Please fin enclosed herewith Audited Financial Results for the quarter and Financial Year ended 31st March, 2026.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported standalone revenue of Rs 6,651 crore (+10.3% YoY) and consolidated revenue of Rs 7,345 crore (+10.1% YoY) for FY2026. Standalone net profit surged 43.6% to Rs 721 crore while consolidated PAT grew 15.7% to Rs 675 crore. The company recognized exceptional items totalling Rs 48.64 crore for the year, comprising an incremental labour code provision (Rs 48.64 crore) and a write-down of Rs 18.35 crore for the Sikkim manufacturing facility being held for sale. A deferred tax asset of Rs 100.27 crore was recognized due to a change in applicable tax rate and tax credit reassessment. The Board recommended dividend of Rs 12 per share (600%), up from Rs 11 (550%) last year. Auditors issued an unmodified opinion on both standalone and consolidated results.
Strong bottom-line growth with expanding margins — standalone PAT up 43.6% and operating margin improving to 16.82% — signals operational efficiency gains, though the Sikkim facility write-down and labour code charge indicate one-time headwinds. Positive for shareholders with higher dividend payout.